Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-25-010531
Filing Date
2025-02-07
Accepted
2025-02-07 16:06:13
Documents
16
Period of Report
2024-11-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm255898d1_8ka.htm   iXBRL 8-K/A 42256
2 EXHIBIT 10.1 tm255898d1_ex10-1.htm EX-10.1 88529
3 EXHIBIT 10.2 tm255898d1_ex10-2.htm EX-10.2 339862
4 EXHIBIT 10.3 tm255898d1_ex10-3.htm EX-10.3 165618
  Complete submission text file 0001104659-25-010531.txt   932046

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ocgn-20241106.xsd EX-101.SCH 3024
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocgn-20241106_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocgn-20241106_pre.xml EX-101.PRE 22365
18 EXTRACTED XBRL INSTANCE DOCUMENT tm255898d1_8ka_htm.xml XML 3550
Mailing Address 11 GREAT VALLEY PARKWAY MALVERN PA 19355
Business Address 11 GREAT VALLEY PARKWAY MALVERN PA 19355 484-328-4701
Ocugen, Inc. (Filer) CIK: 0001372299 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36751 | Film No.: 25601712
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)